Published in Mediators Inflamm on September 19, 2010
Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice. Arthritis Rheum (2012) 1.48
RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med (2013) 1.15
Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol (2015) 1.10
Emerging therapies for systemic lupus erythematosus--focus on targeting interferon-alpha. Clin Immunol (2012) 1.09
Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol (2013) 1.04
Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. BMC Med (2015) 0.97
Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther (2011) 0.92
Critical role of RAGE and HMGB1 in inflammatory heart disease. Proc Natl Acad Sci U S A (2015) 0.87
Toll-Like Receptors in the Pathogenesis of Autoimmune Diseases. Adv Pharm Bull (2015) 0.81
Endosomal Toll-like receptors in clinically overt and silent autoimmunity. Immunol Rev (2016) 0.79
Roles of B Cell-Intrinsic TLR Signals in Systemic Lupus Erythematosus. Int J Mol Sci (2015) 0.79
Systemic lupus erythematosus: genomics, mechanisms, and therapies. Clin Dev Immunol (2012) 0.78
A conserved region within interferon regulatory factor 5 controls breast cancer cell migration through a cytoplasmic and transcription-independent mechanism. Mol Cancer (2015) 0.75
U1-RNP and Toll-like receptors in the pathogenesis of mixed connective tissue diseasePart II. Endosomal TLRs and their biological significance in the pathogenesis of mixed connective tissue disease. Reumatologia (2015) 0.75
Potential roles of nucleotide-binding oligomerization domain 2 in the pathogenesis of systemic lupus erythematosus. Rheumatol Int (2014) 0.75
Pathogen recognition and innate immunity. Cell (2006) 44.14
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 17.57
IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature (2005) 13.23
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol (2007) 12.00
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol (2004) 9.42
MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell (1998) 8.73
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60
IRF family of transcription factors as regulators of host defense. Annu Rev Immunol (2001) 8.18
TLR signaling. Semin Immunol (2007) 8.16
IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 6.79
Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet (2008) 6.42
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity (2006) 6.00
Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci (2008) 5.95
Toll-like receptor signaling pathways. Science (2003) 5.86
Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol (2004) 5.71
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science (2006) 5.30
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
NF-kappaB signaling pathways in mammalian and insect innate immunity. Genes Dev (2001) 4.70
IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc Natl Acad Sci U S A (2003) 4.33
Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet (2008) 4.33
Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol (2001) 4.23
Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature (2002) 3.74
The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med (1998) 3.70
A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A (2006) 3.70
Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med (2003) 3.50
Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med (2005) 3.43
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. Immunity (2007) 3.30
The interface between innate and adaptive immunity. Nat Immunol (2004) 3.28
Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med (2003) 3.24
Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity (2001) 3.18
Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol (2008) 2.89
A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol (2006) 2.89
Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci U S A (2004) 2.89
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab (2007) 2.84
Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun (2009) 2.78
Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat Immunol (2004) 2.58
The innate immune system in SLE: type I interferons and dendritic cells. Lupus (2008) 2.52
Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum (1982) 2.40
Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A (2005) 2.39
Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol (2007) 2.32
Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum (2000) 2.28
Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol (2007) 2.12
A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity. J Exp Med (2007) 2.03
Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol (2007) 1.96
Genetic modifiers of systemic lupus erythematosus in FcgammaRIIB(-/-) mice. J Exp Med (2002) 1.77
Peptide-mediated interference of TIR domain dimerization in MyD88 inhibits interleukin-1-dependent activation of NF-{kappa}B. J Biol Chem (2005) 1.75
Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol (2009) 1.73
Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci U S A (2009) 1.70
Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol (2005) 1.69
Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol (2007) 1.69
Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol (2007) 1.68
Association study of Toll-like receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus. J Rheumatol (2007) 1.63
TLR pathways and IFN-regulatory factors: to each its own. Eur J Immunol (2007) 1.62
MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression. FEBS Lett (2003) 1.59
Toll-like receptor 9 signaling protects against murine lupus. Arthritis Rheum (2006) 1.56
Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum (1997) 1.55
Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol (2006) 1.51
Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum (2006) 1.49
Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett (2006) 1.43
Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum (2005) 1.40
Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. Int Immunol (2006) 1.40
Inhibitors of TLR-9 act on multiple cell subsets in mouse and man in vitro and prevent death in vivo from systemic inflammation. J Immunol (2005) 1.36
Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond. Vaccine (2008) 1.35
Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. J Leukoc Biol (2007) 1.34
Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol (2008) 1.33
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine (2005) 1.33
Crystal structures of IRAK-4 kinase in complex with inhibitors: a serine/threonine kinase with tyrosine as a gatekeeper. Structure (2006) 1.32
Meta-analysis and imputation identifies a 109 kb risk haplotype spanning TNFAIP3 associated with lupus nephritis and hematologic manifestations. Genes Immun (2009) 1.25
A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling. Mol Cell Biol (2005) 1.24
A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci U S A (2003) 1.23
Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology (2009) 1.23
Toll-like receptor 9-independent aggravation of glomerulonephritis in a novel model of SLE. Int Immunol (2006) 1.21
Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med (2009) 1.20
Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum (2008) 1.20
Critical role of TLR2 and TLR4 in autoantibody production and glomerulonephritis in lpr mutation-induced mouse lupus. J Immunol (2009) 1.18
Association study of Toll-like receptor 9 gene polymorphism in Korean patients with systemic lupus erythematosus. Tissue Antigens (2005) 1.14
Association of the polymorphism for Toll-like receptor 2 with type 1 diabetes susceptibility. Ann N Y Acad Sci (2004) 1.14
Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis (2008) 1.10
Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol (2007) 1.07
Toll-like receptors and innate immune responses in systemic lupus erythematosus. Arthritis Res Ther (2007) 1.07
Genetic variation in toll-like receptor 9 and susceptibility to systemic lupus erythematosus. Arthritis Rheum (2006) 1.05
Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) (2007) 1.04
Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol (2007) 1.04
Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese. Rheumatology (Oxford) (2005) 0.99
Circulating DNA in systemic lupus erythematosus. Isolation and characterization. J Clin Invest (1984) 0.99
CD40 ligand expressed on B cells in the BXSB mouse model of systemic lupus erythematosus. J Immunol (1997) 0.95
A Toll for lupus. Lupus (2005) 0.92
Innate immunity, epigenetics and autoimmunity in rheumatoid arthritis. Mol Immunol (2009) 0.92
The lupus-prone BXSB strain: the Yaa gene model of systemic lupus erythematosus. Springer Semin Immunopathol (1992) 0.88
IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. Bioorg Med Chem Lett (2008) 0.87
Toll-like receptor 7 (TLR7) modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells. Ann Rheum Dis (2009) 0.85
Regression of systemic lupus erythematosus after development of an acquired toll-like receptor signaling defect and antibody deficiency. Arthritis Rheum (2009) 0.84
Dynamics of the RING domain from human TRAF6 by 15N NMR spectroscopy: implications for biological function. Biochemistry (2008) 0.82
Comparison of the American-European Consensus Group Sjogren's syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis (2013) 2.21
Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors. J Exp Med (2008) 1.88
Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. Nat Genet (2013) 1.79
T cell epitopes of the La/SSB autoantigen in humanized transgenic mice expressing the HLA class II haplotype DRB1*0301/DQB1*0201. Arthritis Rheum (2007) 1.50
Genome-wide DNA methylation patterns in naive CD4+ T cells from patients with primary Sjögren's syndrome. Arthritis Rheumatol (2014) 1.20
Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood (2009) 1.17
Cutting edge: Transitional T3 B cells do not give rise to mature B cells, have undergone selection, and are reduced in murine lupus. J Immunol (2007) 1.10
Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis (2010) 1.01
Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun (2008) 1.01
Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine (2011) 0.99
The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes. Infect Immun (2009) 0.99
Anti-nuclear antibody production and autoimmunity in transgenic mice that overexpress the transcription factor Bright. J Immunol (2007) 0.92
Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine (2012) 0.91
CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PD-L1. Infect Immun (2010) 0.86
Toll-like receptor 7 (TLR7) modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells. Ann Rheum Dis (2009) 0.85
Global analysis of B cell selection using an immunoglobulin light chain-mediated model of autoreactivity. J Exp Med (2012) 0.83
Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa mice. Arthritis Rheumatol (2014) 0.82
Early and dynamic polarization of T cell membrane rafts and constituents prior to TCR stop signals. J Immunol (2007) 0.82
Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sjögren's syndrome. Arthritis Rheumatol (2014) 0.81
Autoimmunity as a result of escape from RNA surveillance. J Immunol (2006) 0.81
Proteinuria of nonautoimmune origin in wild-type FVB/NJ mice. Comp Med (2007) 0.81
Anthrax lethal toxin-induced gene expression changes in mouse lung. Toxins (Basel) (2011) 0.79
Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization. Vaccine (2013) 0.78
MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen. Toxins (Basel) (2012) 0.77
Toll-like receptors in systemic lupus erythematosus: potential targets for therapeutic intervention. Curr Allergy Asthma Rep (2012) 0.75
Detection of a rare oligo(A) repeat tract mutation (8As-->7As) in the sequence encoding the La/SS-B autoantigen. Anal Biochem (2007) 0.75